Processing...
Clinical Trials for Pancreas Cancer
Search
Search
There are 233 active trials for advanced/metastatic pancreas cancer.
Click on a trial to see more information.
233 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Patients with incurable locally advanced, recurrent, or metastatic solid tumors who lack appropriate standard treatment receive once-daily oral CP-383, an investigational dual DHODH/TEAD4 inhibitor. Dose expansion focuses on selected cancers, including colorectal, small-cell lung, and head and neck cancers, with some cohorts defined by tumor alterations.
ClinicalTrials.gov ID: NCT07030257
TrialFetch AI summary: Adults with measurable advanced bladder, lung, head and neck, esophageal, or pancreatic cancer and ECOG 0–1 receive intravenous PF-08046876, an antibody–drug conjugate targeting integrin beta-6 that delivers a camptothecin-class topoisomerase I inhibitor. Dose escalation requires progression after standard therapy; dose optimization and expansion cohorts allow up to two prior systemic therapy lines for advanced disease.
ClinicalTrials.gov ID: NCT07090499
TrialFetch AI summary: Adults with measurable advanced solid tumors that have progressed after standard therapy or lack a standard treatment option receive a single intravenous infusion of IDOV-Immune. This engineered oncolytic vaccinia virus is designed to replicate preferentially in tumor cells, destroy them, and stimulate antitumor immunity.
ClinicalTrials.gov ID: NCT06910657
TrialFetch AI summary: Adults with previously treated, locally advanced unresectable or metastatic FAP-positive solid tumors receive intravenous LY4337713, an investigational lutetium-177 radioligand that targets fibroblast activation protein on cancer-associated fibroblasts to deliver radiation to tumors. Eligible cancers include pancreatic, breast, ovarian, gastric, colorectal, esophageal, and cholangiocarcinoma.
ClinicalTrials.gov ID: NCT07213791
TrialFetch AI summary: Patients with previously treated, progressive advanced or metastatic colorectal adenocarcinoma, non-small cell lung cancer, or pancreatic ductal adenocarcinoma who have no tolerable standard treatment options receive intravenous PHN-012, an investigational antibody–drug conjugate. Its target antigen and payload have not been disclosed.
ClinicalTrials.gov ID: NCT07127874
TrialFetch AI summary: Patients with advanced or metastatic MUC-1–overexpressing solid tumors after standard therapy receive M0324 alone or with pembrolizumab; the pembrolizumab cohort also requires progression on or after prior checkpoint inhibition. A separate cohort with previously untreated metastatic pancreatic ductal adenocarcinoma receives M0324 plus mFOLFIRINOX. M0324 is an investigational MUC-1 × CD40 bispecific antibody designed to activate immune cells near MUC-1–expressing tumors.
ClinicalTrials.gov ID: NCT07166601
TrialFetch AI summary: Adults with measurable, homozygous MTAP-deleted solid tumors and ECOG performance status 0–1 receive oral BAY 3713372, an investigational PRMT5 inhibitor designed to target the PRMT5–MTA complex. Expansion cohorts include non–small cell lung and pancreatic ductal adenocarcinomas and may test BAY 3713372 with unspecified combination partners.
ClinicalTrials.gov ID: NCT06914128
TrialFetch AI summary: Adults with previously treated, advanced CA19-9–expressing solid tumors and no standard treatment option likely to benefit them receive BNT329, an investigational CA19-9–directed antibody–drug conjugate carrying a topoisomerase I inhibitor. Cohorts test different dosing schedules, one with a CA19-9–targeting antibody given before BNT329; a previously treated pancreatic cancer cohort compares two BNT329 doses.
ClinicalTrials.gov ID: NCT07186842
TrialFetch AI summary: Adults with unresectable locally advanced or metastatic solid tumors who have exhausted, cannot tolerate, or lack standard treatment options receive MRG007 (ARR-217), an investigational antibody–drug conjugate targeting CDH17 and carrying the cytotoxic payload exatecan. Patients must have measurable disease, ECOG performance status 0–1, and tumor tissue available for CDH17 testing or be willing to undergo biopsy.
ClinicalTrials.gov ID: NCT07066657
TrialFetch AI summary: For patients with unresectable locally advanced or metastatic KRAS-mutated or KRAS-amplified solid tumors who have received, are ineligible for, or decline standard care, this study evaluates BMS-986523 alone or with pembrolizumab, cetuximab, or gemcitabine plus nab-paclitaxel. BMS-986523 is an investigational protein-degradation therapy with an undisclosed target; the pembrolizumab arm additionally requires PD-L1 expression ≥50%.
ClinicalTrials.gov ID: NCT07223047